TD Cowen analyst Josh Jennings maintains $Boston Scientific (BSX.US)$ with a buy rating, and maintains the target price at $100.
According to TipRanks data, the analyst has a success rate of 54.4% and a total average return of 4.8% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Boston Scientific (BSX.US)$'s main analysts recently are as follows:
The expectation is that Boston Scientific will surpass the market's third-quarter estimates and potentially elevate its guidance once more. The company is currently witnessing strong momentum, propelled by multiple significant factors, such as Farapulse, which is consistently gaining market share over RF and cryo technologies.
Boston Scientific's upcoming OPTION trial outcomes, anticipated to be presented in November at AHA 2024, are poised to potentially expand the addressable market for the left-atrial-appendage-closure (LAAC) device, thereby accelerating sales growth. Following a survey of additional electrophysiologists and in-depth discussions with physicians, it was broadly anticipated that the OPTION trial is expected to achieve its primary endpoints. A majority of the physicians consulted forecast that a favorable outcome from the OPTION trial would lead to a swift increase in procedure volumes and catalyze a rapid uptick in LAAC volumes.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
TD Cowen分析師Josh Jennings維持$波士頓科學 (BSX.US)$買入評級，維持目標價100美元。
根據TipRanks數據顯示，該分析師近一年總勝率為54.4%，總平均回報率為4.8%。
此外，綜合報道，$波士頓科學 (BSX.US)$近期主要分析師觀點如下：
預計波士頓科學將超過市場第三季度的預期，並有可能再次提高其指引。在多個重要因素的推動下，該公司目前勢頭強勁，例如Farapulse，與射頻和低溫技術相比，Farapulse的市場份額持續增加。
波士頓科學即將發佈的OPTION試驗結果預計將於11月在AHA 2024上公佈，有望擴大左心室附屬物封閉（LAAC）設備的潛在市場，從而加速銷售增長。在對其他電生理學家進行了調查並與醫生進行了深入討論之後，人們普遍預計OPTION試驗有望達到其主要終點。大多數接受諮詢的醫生預測，OPTION試驗的良好結果將導致手術量的迅速增加，並催化LAAC數量的快速增長。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
